Becaplermin biosimilar (Tasly Pharmaceutical/Essex Bio-Technology)

贝卡普勒明生物类似药 (Tasly Pharmaceutical/Essex Bio-Technology)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBecaplermin biosimilar (Tasly Pharmaceutical/Essex Bio-Technology)
Drug Alias NamerhPDGF-BB (Tasly Pharmaceutical/Essex Bio-Technology)贝卡普勒明生物仿制药 (Tasly Pharmaceutical/Essex Bio-Technology)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionPlatelet-derived growth factor receptor agonists
TargetsPlatelet-derived growth factor receptor
Therapy Area/IndicationsDiabetic Foot
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTasly Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsDiabetic Foot
Inactive IndicationsN/A

Other Information

ATC CodeA01AD08D03AX06
Related LinksN/A